• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Simavita Releases ASX Appendix 4C for Q4 2015

    Vivien Diniz
    Jan. 22, 2016 10:00AM PST
    Biotech Investing

    Simavita Limited (ASX:SVA,TSXV:SV) released its ASX Appendix 4C for the quarter ended December 31, 2015.

    Simavita Limited (ASX:SVA,TSXV:SV) released its ASX Appendix 4C for the quarter ended December 31, 2015. The company is also pleased to provide data demonstrating the growing adoption of SIM™ in both domestic and international markets.
    According to the press release:

    ASX Appendix 4C – December 31, 2015
    Cash receipts from customers for the quarter were $196,041 taking the total for the first six months of the 2016 financial year to $419,857. These figures represent a 50% increase quarter on quarter and a 90% increase over the corresponding first half of financial year 2015.
    Highlights during and immediately post the December quarter included:

    • North American sales team signed agreements covering 20 sites (compared with 9 sites in the previous quarter). Number of sites contracted in North America now totalling 36, with 3,859 beds.
    • ANZ sales team executed new agreements across three aged care sites, and obtained agreement for pilot programs at a further three sites. The total number of aged care sites contracted in Australia is now 62, with a total of 5,383 beds.
    • First Australian pilot program conducted in home care setting with positive results. Two additional home care providers have requested to participate in similar trials.
    • Significant funding ($469,450) was awarded by the Queensland Health Department to fund the deployment of SIM™ in rehabilitation wards and an incontinence clinic (the equivalent to 18 aged care sites) at two major hospitals in Brisbane over the next two years. Immediately post the quarter, deployment commenced in January 2016.
    • Entering into a binding heads of agreement to integrate Simavita’s Smart Incontinence System (SIM™) into Health Metric’s eCase® electronic care plan solution.
    • The Company further strengthened its global patent portfolio with the granting of three new patents during the quarter.
    • Positive research results evidencing clinical improvements from SIM™ deployment continue to be generated, supporting the adoption of SIM™ in key markets.

    Immediately post the quarter:

    • Simavita received $1,266,862 under the Australian Government’s Research and Development Tax Incentive Scheme, relating to the year ended 30 June 2015.
    • The Company has closed the first tranche of a capital raising, with $600,000 raised, plus confirmed a further $1,000,000 commitment by entities associated with a Director of the Company which is subject to shareholder approval. The Company has also announced it will initiate a CDI purchase plan for all shareholders.
    • Pilots are currently underway with customers who have in excess of 9700 beds across 123 sites.

    Simavita’s CEO, Mrs. Philippa Lewis commented:

    Our sales teams have worked hard in the December quarter to sign new customers and convert others to the SaaS model, which will deliver important annuity benefits over the longer term. As a result, we are seeing continued momentum around our new customer agreements and the pipeline of pilots is growing rapidly. Pleasingly, we are starting to conduct pilots with larger healthcare chains.

    Click here to view the full press release. 

    queenslandsimavitaaustraliatax incentive
    The Conversation (0)

    Go Deeper

    AI Powered
    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Lab worker putting samples on microscope.

    Top 4 Small-cap ASX Biotech Stocks of 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×